Intellia Therapeutics (NTLA) Projected to Release Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Intellia Therapeutics to post earnings of ($0.7970) per share and revenue of $9.74 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.80). The business had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company’s revenue was down 46.4% on a year-over-year basis. During the same period last year, the business earned ($0.98) EPS. On average, analysts expect Intellia Therapeutics to post ($3.21) EPS for the current fiscal year and ($2.32) EPS for the next fiscal year.

Intellia Therapeutics Stock Up 1.7%

Intellia Therapeutics stock opened at $11.86 on Wednesday. The company has a fifty day simple moving average of $12.20 and a 200-day simple moving average of $13.06. Intellia Therapeutics has a 12-month low of $7.95 and a 12-month high of $18.48.

Analyst Ratings Changes

Several research firms recently commented on NTLA. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. Evercore raised Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. Citizens Jmp reiterated a “market outperform” rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have assigned a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.57.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 9,000 shares of Intellia Therapeutics stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $11.99, for a total transaction of $107,910.00. Following the sale, the chief executive officer owned 1,138,064 shares in the company, valued at approximately $13,645,387.36. The trade was a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.50% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.